Cleveland Clinic Cancer Center (Taussig) Outcomes
Lymphoma
Lymphoma
As part of Taussig Cancer Institute's mission to improve patient outcomes, lymphoma program staff constantly update and review standard-of-care treatments, participate in clinical trials of new treatment strategies, and work closely with the blood and marrow transplant program. The results of this carefully coordinated approach are reflected in the outcomes shown in the survival curves included here.
Five-Year Overall Survival of Patients With Aggressive Non-Hodgkin Lymphoma by Disease Type (N = 1272)
2009-2019
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Burkitt Lymphoma (N = 56) | 40 | 33 | 29 | 23 | 10 |
| DLBCL (N = 1059) | 821 | 619 | 461 | 349 | 219 |
| Mantle Cell (N = 157) | 141 | 108 | 88 | 60 | 40 |
DLBCL = diffuse large B-cell lymphoma
Five-Year Overall Survival of Patients With Indolent Non-Hodgkin Lymphomaᵃ (Follicular Lymphoma vs. Other Indolent Subtypes) (N = 1108)
2009-2019
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Follicular (N = 553) | 516 | 420 | 341 | 262 | 171 |
| Nonfollicular (N = 555) | 517 | 425 | 333 | 259 | 159 |
ᵃIncludes Waldenstoms macroglobulinemia, lymphoplasmacytic, marginal b-cell, splenic marginal b cell, cutaneous t-cell
Five-Year Overall Survival of Patients With Hodgkin Lymphoma (N = 407)
2009-2019
Five-Year Overall Survival of Patients With Chronic Lymphocytic Leukemiaᵃ (N = 510)
2009-2019
ᵃB-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
